Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence

被引：28
作者：
Akazawa, Yuko [1 ]
Fukuda, Daisuke [2 ]
Fukuda, Yutaka [2 ]
机构：
[1] Nagasaki Univ Hosp, Dept Gastroenterol & Hepatol, 1-7-1 Sakamoto, Nagasaki 8528501, Japan
[2] Fukuda Yutaka Surg Clin, Nagasaki, Japan
来源：
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2016年 / 9卷 / 06期
关键词：
Vonoprazan; H; pylori; PPI; Takecab; potassium-competitive acid blocker; P-CAB; TAK-438; COMPETITIVE ACID BLOCKER; TRIPLE THERAPY; TAK-438; VONOPRAZAN; GASTRIC-CANCER; CLARITHROMYCIN; EFFICACY; TOLERABILITY; RESISTANCE; INFECTION; SAFETY;
D O I：
10.1177/1756283X16668093
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Stable suppression of gastric acid secretion is a crucial factor in Helicobacter pylori eradication. Vonoprazan is a potassium-competitive acid blocker recently approved for use in Japan. As vonoprazan has a long duration of action and causes rapid and strong inhibition of gastric acid secretion, it has gained clinical attention for treating erosive oesophagitis, peptic ulcers, and H. pylori infection. In this review, we discuss the recent knowledge regarding the safety and efficacy of vonoprazan, focusing on its use in H. pylori eradication. The latest literature and our clinical experience have shown that vonoprazan-based therapies have satisfactory eradication rates. Additionally, vonoprazan-based therapies are associated with similar rates of adverse events as standard triple therapies with conventional proton-pump inhibitors.
引用
收藏
页码：845 / 852
页数：8
相关论文
共 51 条
[31]   A Randomized Controlled Trial Comparing the First-Line Eradication Rate Using Vonoprazan or PPI for Helicobacter pylori Infectious Gastritis [J].
Maruyama, Masafumi ;
Kubota, Daisuke ;
Miyajima, Masayuki ;
Kimura, Takefumi ;
Tokutake, Koujiro ;
Imai, Ryujiro ;
Fujisawa, Toru ;
Mori, Hiromitsu ;
Matsuda, Yoshiaki ;
Wada, Shuichi ;
Kiyosawa, Kendo .
GASTROENTEROLOGY, 2016, 150 (04) :S1269-S1269
[32]   Potassium-Competitive Acid Blocker Antisecretory Therapy Improves H. pylori Eradication [J].
Matsumoto, Hiroshi ;
Kamada, Tomoari ;
Oosawa, Motoyasu ;
Katsumata, Ryo ;
Fujita, Minoru ;
Nakato, Rui ;
Murao, Takahisa ;
Ishii, Manabu ;
Kusunoki, Hiroaki ;
Haruma, Ken ;
Shiotani, Akiko .
GASTROENTEROLOGY, 2016, 150 (04) :S878-S878
[33]   Helicobacter pylori and antibiotic resistance [J].
Megraud, Francis .
GUT, 2007, 56 (11) :1502-1502
[34]   The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy [J].
Megraud, Francis .
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2012, 5 (02) :103-109
[35]  
MENDLEIN J, 1990, J BIOL CHEM, V265, P5030
[36]   Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan [J].
Miki, I ;
Aoyama, N ;
Sakai, T ;
Shirasaka, D ;
Wambura, CM ;
Maekawa, S ;
Kuroda, K ;
Tamura, T ;
Kita, T ;
Sakaeda, T ;
Okumura, K ;
Kasuga, M .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2003, 15 (01) :27-33
[37]   Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study [J].
Murakami, Kazunari ;
Sakurai, Yuuichi ;
Shiino, Madoka ;
Funao, Nobuo ;
Nishimura, Akira ;
Asaka, Masahiro .
GUT, 2016, 65 (09) :1439-1446
[38]   Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan [J].
Nakamura, Shotaro ;
Sugiyama, Toshiro ;
Matsumoto, Takayuki ;
Iijima, Katsunori ;
Ono, Shouko ;
Tajika, Masahiro ;
Tari, Akira ;
Kitadai, Yasuhiko ;
Matsumoto, Hiroshi ;
Nagaya, Tadanobu ;
Kamoshida, Toshiro ;
Watanabe, Norihiko ;
Chiba, Toshimi ;
Origasa, Hideki ;
Asaka, Masahiro .
GUT, 2012, 61 (04) :507-513
[39]  
Park J., 2014, INT J CELL BIOL, P1, DOI DOI 10.1155/2014/715867
[40]   Novel approaches to the pharmacological blockade of gastric acid secretion [J].
Parsons, ME ;
Keeling, DJ .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (04) :411-421
123456